Back to Studies
P1063
Phase I/II Safety and Efficacy Investigation of Atorvastatin for Treatment of Increased LDL-Cholesterol in HIV-Infected children, Adolescents, and Young Adults
Primary Protocol Team Members
Summary
P1063 is a Phase I/II study of atorvastatin in HIV-infected participants ≥ 10 to < 24 years of age. The study is designed to evaluate the safety and efficacy (based on direct LDL-cholesterol levels) of escalating doses of atorvastatin in participants on a stable antiretroviral regimen. Participants are followed on atorvastatin for 48 weeks.
Loading study documents...
Loading study sites...
Loading study protocol team...
Loading study press...
Loading study publications/presentations...